ALX Oncology Holdings Inc. (ALXO) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 13, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 6, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ALXO SEC filings page.
This page shows ALX Oncology Holdings Inc. (ALXO) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
The development-stage model is spending less, but cash consumption continues while the equity cushion thins.
R&D spending fell from$141.8M to$77.0M , while the net loss also narrowed, indicating recent improvement is tied more to reduced investment than operating scale. Operating cash flow of-$84.1M nearly matched free cash flow of-$84.4M , showing that reported losses are translating into cash use with little non-cash distortion.
Over the latest year, total equity fell from
Reported liquidity equals 6.9 months of the latest annual operating outflow, framing the cash position against continued funding needs. Shares outstanding rose from 53.4M to 131.6M across the latest two years, so the per-share loss improvement cannot be read as purely operating progress.
Financial Health Signals
ALX Oncology Holdings Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
ALX Oncology Holdings Inc. passes 1 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
ALX Oncology Holdings Inc. reported a net loss of $101.7M while operations used $84.1M of cash. With neither figure positive, the ratio between the two carries no quality signal.
ALX Oncology Holdings Inc. reported an operating loss of $104.0M against $1.6M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
ALX Oncology Holdings Inc.'s EBITDA was -$17.9M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 32.2% from the same quarter a year earlier. Against the prior quarter it is up 4.7%.
ALX Oncology Holdings Inc. reported -$18.0M in net income in Q2 2026. This represents an increase of 30.7% from the same quarter a year earlier. Against the prior quarter it is down 0.2%.
ALX Oncology Holdings Inc. earned -$0.13 per diluted share (EPS) in Q2 2026. Against the prior quarter it is up 23.5%.
Not reported for Q2 2026.
Cash & Balance Sheet
ALX Oncology Holdings Inc. recorded an outflow of $16.1M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents an increase of 31.5% from the same quarter a year earlier. Against the prior quarter it is up 14.0%.
ALX Oncology Holdings Inc. held $22.7M in cash against $9.7M in long-term debt as of Q2 2026.
Not reported for Q2 2026.
Margins & Returns
ALX Oncology Holdings Inc.'s ROE was -13.2% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 27.1 percentage points from the same quarter a year earlier. Against the prior quarter it is down 1.4 percentage points.
Not reported for Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Capital Allocation
ALX Oncology Holdings Inc. invested $13.1M in research and development in Q2 2026. This represents a decrease of 27.1% from the same quarter a year earlier. Against the prior quarter it is down 3.4%.
ALX Oncology Holdings Inc. invested $17K in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 63.8% from the same quarter a year earlier. Against the prior quarter it is down 66.0%.
Not reported for Q2 2026.
ALXO Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $13.1M-27.1% | $13.6M-43.0% | N/A | $17.4M-34.1% | $18.0M-48.0% | $23.9M-24.7% | N/A | $26.5M-42.2% |
| SG&A Expenses | $5.1M-5.8% | $5.4M-32.4% | N/A | $5.1M-16.5% | $5.5M-20.7% | $7.9M+31.2% | N/A | $6.1M-18.8% |
| Operating Income | -$18.0M+32.3% | -$19.0M+40.4% | N/A | -$22.5M+30.8% | -$26.6M+35.8% | -$31.8M+15.7% | N/A | -$32.6M+38.9% |
| EBITDA | -$17.9M+32.2% | -$18.8M+40.5% | N/A | -$22.3M+31.0% | -$26.4M+36.0% | -$31.6M+15.8% | N/A | -$32.4M+39.0% |
| Interest Expense | $285K-29.6% | $331K-18.5% | N/A | $408K-8.5% | $405K-5.6% | $406K-4.9% | N/A | $446K+14.1% |
| Net Income | -$18.0M+30.7% | -$17.9M+41.7% | N/A | -$22.1M+27.9% | -$25.9M+34.1% | -$30.8M+13.6% | N/A | -$30.7M+39.8% |
| EPS (Basic) | -$0.13+73.5% | -$0.17+70.7% | -$0.42+20.8% | -$0.41+29.3% | -$0.49+35.5% | -$0.58+18.3% | -$0.53+42.4% | -$0.58+53.2% |
| EPS (Diluted) | -$0.13 | -$0.17 | -$0.42 | -$0.41+29.3% | -$0.49+35.5% | -$0.58+18.3% | -$0.53+42.4% | -$0.58+53.2% |
| Diluted Shares (Avg) | 136M | 105M | N/A | 54M+1.7% | 53M+3.1% | 53M+6.5% | N/A | 53M+28.1% |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Income Tax.
ALXO Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $160.8M+68.7% | $178.3M+47.5% | $59.0M-60.0% | $82.7M-55.5% | $95.3M-55.6% | $120.9M-43.1% | $147.8M-39.1% | $185.7M-15.6% |
| Current Assets | $143.5M+68.3% | $145.6M+42.0% | $50.7M-62.2% | $66.5M-57.3% | $85.3M-49.5% | $102.5M-38.9% | $134.4M-28.8% | $155.9M-21.7% |
| Cash & Equivalents | $22.7M+17.5% | $32.3M+56.6% | $16.4M-6.8% | $23.4M+45.6% | $19.3M+24.3% | $20.6M+46.8% | $17.6M-21.6% | $16.1M-17.8% |
| Short-Term Investments | $115.5M+92.5% | $108.0M+39.9% | $28.4M-74.2% | $37.2M-71.9% | $60.0M-57.5% | $77.2M-46.2% | $110.2M-31.3% | $132.5M-22.3% |
| Long-Term Investments | $15.1M+257.9% | $28.8M+214.2% | $3.5M-0.9% | $5.8M-58.4% | $4.2M-85.6% | $9.2M-66.1% | $3.5M-90.0% | $14.0M+118.1% |
| Total Liabilities | $24.6M-20.3% | $27.0M-17.2% | $33.1M-3.2% | $37.9M-22.5% | $30.9M-44.1% | $32.6M-32.7% | $34.2M-35.4% | $48.9M-4.8% |
| Current Liabilities | $14.8M-21.6% | $20.2M+7.7% | $24.6M+32.7% | $27.7M-14.3% | $18.8M-51.0% | $18.7M-41.8% | $18.5M-48.6% | $32.3M-8.0% |
| Non-Current Liabilities | $9.9M-18.2% | $6.8M-50.9% | $8.5M-45.6% | $10.2M-38.4% | $12.1M-28.5% | $13.9M-14.6% | $15.7M-7.0% | $16.6M+2.2% |
| Long-Term Debt | $9.7M+38.7% | $3.3M-60.0% | $4.5M-52.1% | $5.8M-41.4% | $7.0M-28.4% | $8.2M-15.2% | $9.5M-1.8% | $9.8M+2.7% |
| Total Equity | $136.2M+111.4% | $151.3M+71.4% | $26.0M-77.1% | $44.8M-67.3% | $64.4M-59.6% | $88.3M-46.2% | $113.6M-40.1% | $136.8M-18.9% |
| Retained Earnings | -$758.7M-11.9% | -$740.7M-13.6% | -$722.8M-16.4% | -$700.0M-18.2% | -$677.8M-20.8% | -$651.9M-24.9% | -$621.1M-27.7% | -$592.0M-34.3% |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill.
ALXO Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$16.1M+31.4% | -$18.6M+24.4% | -$19.0M+40.8% | -$17.1M+32.6% | -$23.4M+11.9% | -$24.7M+35.0% | -$32.0M+19.2% | -$25.4M+18.6% |
| Depreciation & Amortization | $100K-50.0% | $150K-28.9% | $151K-29.4% | $200K0.0% | $200K0.0% | $211K-1.4% | $214K+3.4% | $200K0.0% |
| Stock-Based Compensation | $2.7M+25.6% | $2.5M-51.9% | N/A | $2.5M-63.7% | $2.1M-70.5% | $5.2M-25.8% | N/A | $7.0M-0.2% |
| Capital Expenditures | $17K-63.8% | $50K-16.7% | $49K-18.3% | $56K-62.4% | $47K-47.8% | $60K-59.5% | $60K-59.5% | $149K-88.6% |
| Free Cash Flow | -$16.1M+31.5% | -$18.7M+24.4% | -$19.0M+40.7% | -$17.1M+32.8% | -$23.5M+12.0% | -$24.7M+35.1% | -$32.1M+19.4% | -$25.5M+21.4% |
| Investing Cash Flow | $6.5M-70.8% | -$105.0M-479.9% | $11.2M-66.1% | $21.4M-16.7% | $22.3M+2360.4% | $27.6M+4.4% | $33.2M+299.1% | $25.7M+100.5% |
| Financing Cash Flow | $137K+161.7% | $139.6M+214661.5% | $678K+106.7% | -$159K-163.3% | -$222K-100.8% | $65K-97.9% | $328K-99.4% | $251K+326.1% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
ALXO Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -13.2%+27.1pp | -11.8%+23.0pp | N/A | -49.4%-27.0pp | -40.3%-15.6pp | -34.8%-13.2pp | N/A | -22.4%+7.8pp |
| Return on Assets | -11.2%+16.1pp | -10.1%+15.4pp | N/A | -26.8%-10.2pp | -27.2%-8.9pp | -25.4%-8.7pp | N/A | -16.5%+6.6pp |
| Current Ratio | 9.71+5.2x | 7.21+1.7x | 2.07-5.2x | 2.40-2.4x | 4.52+0.1x | 5.47+0.3x | 7.26+2.0x | 4.82-0.8x |
| Debt-to-Equity | 0.070.0x | 0.02-0.1x | 0.17+0.1x | 0.13+0.1x | 0.110.0x | 0.090.0x | 0.080.0x | 0.070.0x |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| ALX Oncology Holdings Inc. ALXO | FY2025 | N/A | -$101.7M | N/A | $174.2M | — |
| MiNK Therapeutics, Inc. INKT | FY2025 | N/A | -$12.5M | N/A | $53.7M | — |
| Artiva Biotherapeutics, Inc. ARTV | FY2025 | $0 | -$83.9M | N/A | $331.0M | — |
| Werewolf Therapeutics, Inc. HOWL | FY2025 | N/A | -$60.8M | N/A | $47.6M | — |
| Applied Therapeutics, Inc. APLT | FY2024 | $455K | -$105.6M | N/A | $14.9M | — |
| Cue Biopharma, Inc. CUE | FY2025 | $27.5M | -$26.6M | -96.9% | $178.8M | 63/100 |
Where ALX Oncology Holdings Inc. Ranks
Frequently Asked Questions
Is ALX Oncology Holdings Inc. profitable?
No, ALX Oncology Holdings Inc. (ALXO) reported a net income of -$101.7M in fiscal year 2025.
What is ALX Oncology Holdings Inc.'s EBITDA?
ALX Oncology Holdings Inc. (ALXO) had EBITDA of -$103.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does ALX Oncology Holdings Inc. have?
As of fiscal year 2025, ALX Oncology Holdings Inc. (ALXO) had $16.4M in cash and equivalents against $4.5M in long-term debt.
What is ALX Oncology Holdings Inc.'s return on equity (ROE)?
ALX Oncology Holdings Inc. (ALXO) has a return on equity of -391.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is ALX Oncology Holdings Inc.'s free cash flow?
ALX Oncology Holdings Inc. (ALXO) recorded an outflow of $84.4M in free cash flow during fiscal year 2025. This represents a 31.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is ALX Oncology Holdings Inc.'s operating cash flow?
ALX Oncology Holdings Inc. (ALXO) recorded an outflow of $84.1M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are ALX Oncology Holdings Inc.'s total assets?
ALX Oncology Holdings Inc. (ALXO) had $59.0M in total assets as of fiscal year 2025, including both current and long-term assets.
What are ALX Oncology Holdings Inc.'s capital expenditures?
ALX Oncology Holdings Inc. (ALXO) invested $212K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does ALX Oncology Holdings Inc. spend on research and development?
ALX Oncology Holdings Inc. (ALXO) invested $77.0M in research and development during fiscal year 2025.
What is ALX Oncology Holdings Inc.'s current ratio?
ALX Oncology Holdings Inc. (ALXO) had a current ratio of 2.07 as of fiscal year 2025, which is generally considered healthy.
What is ALX Oncology Holdings Inc.'s debt-to-equity ratio?
ALX Oncology Holdings Inc. (ALXO) had a debt-to-equity ratio of 0.17 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is ALX Oncology Holdings Inc.'s return on assets (ROA)?
ALX Oncology Holdings Inc. (ALXO) had a return on assets of -172.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is ALX Oncology Holdings Inc.'s P/E ratio?
ALX Oncology Holdings Inc. (ALXO) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $174.2M as of Oct 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is ALX Oncology Holdings Inc.'s price-to-sales ratio?
ALX Oncology Holdings Inc. (ALXO) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $174.2M as of Oct 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does ALX Oncology Holdings Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, ALX Oncology Holdings Inc. (ALXO) held $48.3M in cash, cash equivalents and investments, and reported an operating cash outflow of $84.1M over that year. Dividing the one by the other, the reported balance equals about 7 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is ALX Oncology Holdings Inc.'s Piotroski F-Score?
ALX Oncology Holdings Inc. (ALXO) has a Piotroski F-Score of 1 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are ALX Oncology Holdings Inc.'s earnings high quality?
ALX Oncology Holdings Inc. (ALXO) reported a net loss of $101.7M while operations used $84.1M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can ALX Oncology Holdings Inc. cover its interest payments?
ALX Oncology Holdings Inc. (ALXO) reported an operating loss of $104.0M against $1.6M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.